FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328857581> ?p ?o ?g. }

• W2328857581 endingPage "i29" @default.
• W2328857581 startingPage "i29" @default.
• W2328857581 abstract "Aim: Since 2010 that the combination of platinum / pemetrexed is approved as first line therapy for advanced (locally advanced or metastatic) nonsquamous non-small cell lung cancer (NSCLC). Our aim is to assess the effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous NSCLC in clinical practice. Methods: Consecutive series of patients with advanced nonsquamous NSCLC treated with pemetrexed plus platinum as first-line therapy, at our center, from May 2010 to July 2013. The date of data cutoff was December 12, 2014. Data on demographics, prognostic factors, response, survival and toxicity were retrieved from clinical files. Results: 193 patients were included. Baseline characteristics: median age 64 years (range 34-81); 71% males; 97% adenocarcinoma; 29% never smokers; 26% ECOG performance status (PS) 0, 65% PS 1 and 9% PS 2 or 3; 81% stage IV; 8% received prior therapies with curative intent. The median number of cycles was 6 (range 1–6). 74% received cisplatin plus pemetrexed and the remaining 26% carboplatin plus pemetrexed. One patient had complete response and 14% presented a partial response. Median follow-up time for patients alive at last follow up was 38 months. Median overall survival (OS) was 10 months (95% CI 8.0–12.0), progression-free survival (PFS) was 5 months (95% CI 4.3–5.7) and 12 month survival rate was 45% (95% CI 38.0–52.0). Patients on carboplatin plus pemetrexed had an OS of 13 months (95% CI 8.7–17.3), a PFS of 5 months (95% CI 3.5–6.5) and a 12 month survival rate of 53% (95% CI 39.3–66.7). 45% of patients underwent a second-line therapy and 16% received two or more therapy lines after pemetrexed plus platinum. Male sex, a PS ≥ 1 and absence of prior therapies with curative intent were predictors of a poorer prognosis. Grade 3–4 toxicity was identified only in 18% of patients: hematological (6%) and respiratory infection (5%); 10% of patients were hospitalized for reasons related to therapy. Conclusions: As expected, the OS was lower than what was observed in the clinical trial setting; however, the PFS was similar. The platinum plus pemetrexed combination was well tolerated by patients, with a low hospitalization rate. Disclosure: All authors have declared no conflicts of interest." @default.
• W2328857581 created "2016-06-24" @default.
• W2328857581 creator A5004669734 @default.
• W2328857581 creator A5009837639 @default.
• W2328857581 creator A5014994826 @default.
• W2328857581 creator A5022072674 @default.
• W2328857581 creator A5051950200 @default.
• W2328857581 creator A5053692834 @default.
• W2328857581 creator A5064423963 @default.
• W2328857581 creator A5078369929 @default.
• W2328857581 creator A5024628855 @default.
• W2328857581 date "2015-04-01" @default.
• W2328857581 modified "2023-09-28" @default.
• W2328857581 title "Effectiveness of First-Line Pemetrexed Plus Platinum for Advanced Nonsquamous Non-Small Cell Lung Cancer" @default.
• W2328857581 doi "https://doi.org/10.1093/annonc/mdv050.33" @default.
• W2328857581 hasPublicationYear "2015" @default.
• W2328857581 type Work @default.
• W2328857581 sameAs 2328857581 @default.
• W2328857581 citedByCount "0" @default.
• W2328857581 crossrefType "journal-article" @default.
• W2328857581 hasAuthorship W2328857581A5004669734 @default.
• W2328857581 hasAuthorship W2328857581A5009837639 @default.
• W2328857581 hasAuthorship W2328857581A5014994826 @default.
• W2328857581 hasAuthorship W2328857581A5022072674 @default.
• W2328857581 hasAuthorship W2328857581A5024628855 @default.
• W2328857581 hasAuthorship W2328857581A5051950200 @default.
• W2328857581 hasAuthorship W2328857581A5053692834 @default.
• W2328857581 hasAuthorship W2328857581A5064423963 @default.
• W2328857581 hasAuthorship W2328857581A5078369929 @default.
• W2328857581 hasBestOaLocation W23288575811 @default.
• W2328857581 hasConcept C121608353 @default.
• W2328857581 hasConcept C126322002 @default.
• W2328857581 hasConcept C141071460 @default.
• W2328857581 hasConcept C143998085 @default.
• W2328857581 hasConcept C2776256026 @default.
• W2328857581 hasConcept C2776694085 @default.
• W2328857581 hasConcept C2776907518 @default.
• W2328857581 hasConcept C2777240266 @default.
• W2328857581 hasConcept C2778239845 @default.
• W2328857581 hasConcept C2780739268 @default.
• W2328857581 hasConcept C2781182431 @default.
• W2328857581 hasConcept C2781451048 @default.
• W2328857581 hasConcept C71924100 @default.
• W2328857581 hasConceptScore W2328857581C121608353 @default.
• W2328857581 hasConceptScore W2328857581C126322002 @default.
• W2328857581 hasConceptScore W2328857581C141071460 @default.
• W2328857581 hasConceptScore W2328857581C143998085 @default.
• W2328857581 hasConceptScore W2328857581C2776256026 @default.
• W2328857581 hasConceptScore W2328857581C2776694085 @default.
• W2328857581 hasConceptScore W2328857581C2776907518 @default.
• W2328857581 hasConceptScore W2328857581C2777240266 @default.
• W2328857581 hasConceptScore W2328857581C2778239845 @default.
• W2328857581 hasConceptScore W2328857581C2780739268 @default.
• W2328857581 hasConceptScore W2328857581C2781182431 @default.
• W2328857581 hasConceptScore W2328857581C2781451048 @default.
• W2328857581 hasConceptScore W2328857581C71924100 @default.
• W2328857581 hasLocation W23288575811 @default.
• W2328857581 hasOpenAccess W2328857581 @default.
• W2328857581 hasPrimaryLocation W23288575811 @default.
• W2328857581 hasRelatedWork W2013653877 @default.
• W2328857581 hasRelatedWork W2018515503 @default.
• W2328857581 hasRelatedWork W2049286103 @default.
• W2328857581 hasRelatedWork W2315681365 @default.
• W2328857581 hasRelatedWork W2358450743 @default.
• W2328857581 hasRelatedWork W2378767654 @default.
• W2328857581 hasRelatedWork W2989078112 @default.
• W2328857581 hasRelatedWork W3032772405 @default.
• W2328857581 hasRelatedWork W3196861824 @default.
• W2328857581 hasRelatedWork W4291931441 @default.
• W2328857581 hasVolume "26" @default.
• W2328857581 isParatext "false" @default.
• W2328857581 isRetracted "false" @default.
• W2328857581 magId "2328857581" @default.
• W2328857581 workType "article" @default.